Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q3 FY26 results · Oct–Dec 2025
Alivus Life Sciences reported revenue from operations of ₹672.89 crore (up 4.8% from Q3 FY25) and net profit of ₹150.26 crore (up 9.7% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a standalone basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 672.89 | 641.84 | +4.8% | 587.98 | +14.4% |
| Other income | 13.93 | 10.46 | +33.2% | 14.72 | −5.4% |
| Total income | 686.82 | 652.30 | +5.3% | 602.70 | +14.0% |
| Profit before tax | 198.39 | 185.15 | +7.2% | 174.14 | +13.9% |
| Net profit for the period | 150.26 | 136.96 | +9.7% | 130.03 | +15.6% |
| EPS, basic (₹) | 12.25 | 11.18 | +9.6% | 10.60 | +15.6% |
| Net margin (%) | 22.3 | 21.3 | 22.1 |
Standalone
- Filed with BSE
- 22 Jan 2026, 16:06 IST
- Board meeting
- 22 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE